FitLife Brands, Inc. (FTLF) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. FitLife Brands, Inc. is a provider of nutritional supplements and wellness products operating under four primary brand collections: Legacy FitLife (NDS Nutrition, iSatori, etc.), MRC (Dr. Tobias, Maritime Naturals), and MusclePharm. The company distributes products through wholesale channels (notably GNC) and direct-to-consumer e-commerce platforms (Amazon, company websites). As of May 14, 2025, there were 9,391,072 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $15.94 million | $16.55 million |
| Gross Profit | $6.87 million | $7.29 million |
| Gross Margin | 43.1% | 44.0% |
| Operating Income | $2.96 million | $3.38 million |
| Net Income | $2.02 million | $2.16 million |
| Diluted EPS | $0.20 | $0.21 |
| Operating Cash Flow | $2.33 million | $5.04 million |
| Cash & Equivalents | $5.94 million | $3.29 million (Q1 2024) |
| Total Debt (Term Loans) | $12.00 million | $13.13 million |
| Working Capital | $8.46 million | $6.83 million (Dec 31, 2024) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 4% year-over-year, driven primarily by an 11% decline in MRC revenue and a 6% decline in MusclePharm revenue. This was partially offset by a 5% increase in Legacy FitLife revenue.
- Margin Compression: Gross margin decreased to 43.1% from 44.0%, attributed to lower margins in the MRC and MusclePharm segments.
- Expense Management: Advertising and marketing expenses decreased 14% due to optimization efforts. However, merger and acquisition-related expenses increased 148% to $332,000.
- Cash Flow: Operating cash flow decreased significantly to $2.33 million from $5.04 million in the prior year, primarily due to increases in working capital (specifically accounts receivable and inventory).
- Debt Reduction: The company reduced total term loan principal by $1.125 million during the quarter.
Outlook, Commentary, and Risks
- Brand Performance: Legacy FitLife showed resilience with an 11% increase in online revenue following the resolution of a commercial dispute with GNC in January 2025. MusclePharm wholesale revenue dropped 41% due to a customer taking advantage of Q4 2024 promotions without increasing sell-through, though online revenue for the brand grew 33%.
- Strategic Initiatives: The company launched the "MusclePharm Pro Series" in a pilot program at Vitamin Shoppe stores in March 2025. Management anticipates continued promotional investments in MusclePharm, which may cause margin fluctuations.
- Liquidity: The company maintains a $3.5 million line of credit (extended to April 2026) with no outstanding balance. Management believes cash flow from operations and available credit will suffice for the next 12 months.
- Corporate Actions: A 2-for-1 stock split was effected on February 7, 2025. The Board also extended the share repurchase program on May 13, 2025, authorizing up to $5 million in repurchases over 24 months.
- Risks: The company faces concentration risk with GNC (16% of revenue) and a single vendor (65% of accounts payable). Foreign currency exposure exists due to Canadian operations, though no hedging is currently utilized.
Investor Verification Checklist
- Verify the sustainability of the revenue recovery in the Legacy FitLife segment post-GNC dispute resolution.
- Monitor the impact of promotional spending on MusclePharm margins and the success of the new Pro Series pilot.
- Assess the trend in working capital, specifically the growth in accounts receivable and inventory levels relative to sales.
- Review the company's ability to maintain debt covenants (Fixed Charge Coverage Ratio and Funded Debt to EBITDA) as debt amortization continues.
- Confirm the execution of the extended share repurchase program and its impact on share count.